An expanded access program of erlotinib (Tarceva) in patients with advanced non-small cell lung cancer (NSCLC): data report from Italy

M Tiseo, C Gridelli, S Cascinu, L Crinò, FV Piantedosi… - Lung Cancer, 2009 - Elsevier
BACKGROUND: Erlotinib demonstrated significantly prolonged survival versus placebo in
patients with advanced NSCLC who had progressed after standard chemotherapy. TRUST …
被引用次数：46 相关文章

An expanded access program of erlotinib (Tarceva) in patients with advanced non-small cell lung cancer (NSCLC): Data report from Italy

M Tiseo, C Gridelli, S Cascinu, L Crinò… - Lung …, 2009 - lungcancerjournal.info
Background Erlotinib demonstrated significantly prolonged survival versus placebo in
patients with advanced NSCLC who had progressed after standard chemotherapy. TRUST …

An expanded access program of erlotinib (Tarceva) in patients with advanced non-small cell lung cancer (NSCLC): Data report from Italy

M Tiseo, C Gridelli, S Cascinu, L Crino, F Piantedosi… - LUNG CANCER, 2009 - cris.unibo.it
Background: Erlotinib demonstrated significantly prolonged survival versus placebo in
patients with advanced NSCLC who had progressed after standard chemotherapy. TRUST …

An expanded access program of erlotinib (Tarceva) in patients with advanced non-small cell lung cancer (NSCLC): Data report from Italy

M Tiseo, C Gridelli, S Cascinu, L Crinò, FV Piantedosi… - Lung Cancer, 2009 - infona.pl
Erlotinib demonstrated significantly prolonged survival versus placebo in patients with
advanced NSCLC who had progressed after standard chemotherapy. TRUST is a phase IV …

An expanded access program of erlotinib (Tarceva) in patients with advanced non-small cell lung cancer (NSCLC): Data report from Italy

M Tiseo, C Gridelli, S Cascinu, L Crino, FV Piantedosi… - LUNG CANCER, 2009 - air.unipr.it
Background: Erlotinib demonstrated significantly prolonged survival versus placebo in
patients with advanced NSCLC who had progressed after standard chemotherapy. TRUST …

An expanded access program of erlotinib (Tarceva) in patients with advanced non-small cell lung cancer (NSCLC): data report from Italy

M Tiseo, C Gridelli, S Cascinu… - Lung cancer …, 2009 - pubmed.ncbi.nlm.nih.gov
Background Erlotinib demonstrated significantly prolonged survival versus placebo in
patients with advanced NSCLC who had progressed after standard chemotherapy. TRUST …

[引用][C] An expanded access program of erlotinib (Tarceva) in patients with advanced non-small cell lung cancer (NSCLC): Data report from Italy

M TISEO, C GRIDELLI, O BELVEDERE… - Lung …, 2009 - pascal-francis.inist.fr
An expanded access program of erlotinib (Tarceva) in patients with advanced non-small
cell lung cancer (NSCLC) : Data report from Italy CNRS Inist Pascal-Francis CNRS Pascal …

An expanded access program of erlotinib (Tarceva) in patients with advanced non-small cell lung cancer (NSCLC): data report from Italy

M Tiseo, C Gridelli, S Cascinu, L Crinò, FV Piantedosi… - LUNG CANCER, 2009 - air.unimi.it
Background: Erlotinib demonstrated significantly prolonged survival versus placebo in
patients with advanced NSCLC who had progressed after standard chemotherapy. TRUST …

An expanded access program of erlotinib (Tarceva) in patients with advanced non-small cell lung cancer (NSCLC): data report from Italy.

M Tiseo, C Gridelli, S Cascinu, L Crinò… - Lung Cancer …, 2008 - europepmc.org
Background Erlotinib demonstrated significantly prolonged survival versus placebo in
patients with advanced NSCLC who had progressed after standard chemotherapy. TRUST …

[引用][C] An expanded access program of erlotinib (Tarceva) in patients with advanced non-small cell lung cancer (NSCLC): Data report from Italy

M Tiseo, C Gridelli, S Cascinu, L Crino… - LUNG …, 2009 - irinsubria.uninsubria.it
An expanded access program of erlotinib (Tarceva) in patients with advanced non-small cell
lung cancer (NSCLC): Data report from Italy IRIS IRIS Home Sfoglia Macrotipologie & tipologie …